Drug intelligence / Profile preview

MGD014

Development stage: Phase 1
Lead developer: MacroGenics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MGD014 is an investigational bispecific DART (Dual-Affinity Re-Targeting) molecule developed by MacroGenics for the treatment of HIV infection. It is designed to target both the envelope protein gp120 on HIV-infected cells and CD3 on T cells, thereby redirecting T lymphocytes to kill HIV-infected cells. This mechanism aims to eliminate latent reservoirs of HIV, potentially as part of a "shock-and-kill" strategy in combination with latency-reversing agents. MGD014 is administered parenterally and represents MacroGenics' first clinical DART molecule targeting virus-infected cells[1][2][7].

Targets

Env (HIV-1 envelope glycoprotein)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on MGD014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGD014.

Explore the full profile